Sonnet to acquire Relief Therapeutics to develop atexakin alfa
Category: #health  By Mateen Dalal  Date: 2019-08-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sonnet to acquire Relief Therapeutics to develop atexakin alfa

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics.

Sonnet BioTherapeutics, Inc., a biotechnology company that develops innovative biologic drugs, has recently announced that it has entered into an agreement with Relief Therapeutics Holding SA (RLF). The deal entails the development of atexakin alfa following acquisition of its arm Relief Therapeutics SA via a share exchange transaction.

As per reports, atexakin alfa is a low-dose formulation of IL-6 (interleukin-6), a cytokine with pleiotropic function in various organs and tissues that has successfully cleared Phase I trials. The clinical investigations which were conducted on various settings with more than 700 patients managed to set up a maximum tolerated dose (MTD).

Sources cite that Sonnet will continue atexakin alfa’s (SON-080) development in Chemotherapy Induced Peripheral Neuropathy (CIPN) and could extend to other neuropathies like Diabetic Neuropathy as well.

Speaking on the move, Pankaj Mohan, PhD, Chairman, Sonnet BioTherapeutics, said that after thoroughly studying the clinical and preclinical data, the company feels that atexakin has the potential to be an effective and safe treatment for CIPN, a disease with unmet medical needs.

He said that the company is excited to integrate atexakin to its oncology pipeline, as it possesses the potential to be a commercial blockbuster by treating a patient population that requires undivided medical attention.

Reportedly, the transaction is likely to close at the time when Sonnet would go public, after which, it will take over the development of SON-080 and all its proprietary experimental drugs. Additionally, an international investor has agreed to invest up to $100 million, via a common stock purchase contract, to back Sonnet’s public operations, which is also anticipated to close when Sonnet becomes public.

As per Jay Cross, Chief Financial Officer, Sonnet BioTherapeutics, this agreement offers the company access to capital when needed and the flexibility to follow other avenues of funding. Cross said that the agreement will provide their firms an opportunity to focus on executing their R&D strategy.

Source Credit: https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-acquisition-agreement-114700034.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...